In addition, a significant serum IL-6 levels increase in patients with psoriasis-afflicted or other ICIs-related toxicities after nivolumab treatment while decreases were observed in non-afflicted metastatic melanoma patients (49). Here, IL6 is linked to metastatic melanoma.